Allergan Finance LLC 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
November 11, 2010
WATSON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Registrants telephone number, including area code: (951) 493-5300
(Former name or former address, if changed since last report): Not applicable.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
TABLE OF CONTENTS
Item 8.01. Other Events.
On November 11, 2010, Watson Pharmaceuticals, Inc. (the Company) entered into an underwriting agreement (the Underwriting Agreement) with J.P. Morgan Securities LLC (the Underwriter) and Quiver Inc., a British Virgin Islands limited liability company and a stockholder of the Company (the Selling Stockholder), pursuant to which the Selling Stockholder agreed to sell to the Underwriter 10,537,755 shares of common stock, par value $0.0033 per share of the Company at a price of $49.58 per share. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and is incorporated herein by reference. The offering closed on November 17, 2010. The Company will not receive any of the proceeds from this offering.
The offering was registered under an effective Registration Statement on Form S-3 (Registration No. 333-161404) and a related prospectus supplement, each filed with the Securities and Exchange Commission. The descriptions of the Underwriting Agreement in this report is a summary and is qualified in its entirety by the terms of the Underwriting Agreement.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.